NCT03738943View on ClinicalTrials.gov

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions

Receptor Blockade

Interventions

DRUG

Adenosine Triphosphate

See arm/group descriptions

DRUG

Acetylcholine

See arm/group descriptions

DRUG

Sodium Nitroprusside

See arm/group descriptions

DRUG

Adenosine Diphosphate

See arm/group descriptions

DRUG

Adenosine Monophosphate

See arm/group descriptions

DRUG

Uridine Triphosphate

See arm/group descriptions

DRUG

Adenosine

See arm/group descriptions

DRUG

Vitamin B 6

See arm/group descriptions

DRUG

Pyridoxal 5'-Phosphate

See arm/group descriptions

Trial Locations (1)

80523

Human Performance and Clinical Research Laboratory, Fort Collins

All Listed Sponsors

lead

Colorado State University

OTHER

NCT03738943 - Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults | Biotech Hunter | Biotech Hunter